For years, people taking GLP-1 type drugs (e.g., Ozempic, Wegovy) have noticed that the medicines didn’t just help them to ...

There is initial evidence that low-dose semaglutide may reduce craving and drinking outcomes in individuals with alcohol-use disorder.

Semaglutide shows promise in reducing alcohol cravings and consumption. Could it be a future treatment for AUD?

But the newest study that has gone viral is an even more impressive outcome. Headlines are claiming that researchers have ...

A phase 2 trial shows significant reduction in drinks per drinking day and weekly alcohol craving with low-dose semaglutide. HealthDay News — Low-dose semaglutide seems to reduce craving and certain ...

While more research is needed, experts consider semaglutide a promising development in addressing alcohol addiction.

There are early and suggestive data that GLP-1 drugs reduce alcohol cravings. A large cohort of people with alcohol use ...

showed improvements in certain measures of alcohol use disorder during a nine-week trial. The Danish drugmaker is also testing semaglutide - sold as the diabetes drug Ozempic and the obesity drug ...

The Maryland-based biopharma joins Eli Lilly and Novo Nordisk in trialing a GLP-1 agonist for alcohol- and liver-related ...

Despite comments made by a Novo Nordisk official this week, the company confirmed to BioSpace that it has no additional ...

As the potential of GLP-1 agonists for addiction gains traction, big pharma is also starting to take notice, namely the two ...